Members Login
ACTG Network
  • Home
  • About
    • About the ACTG
    • Leadership and Organizational Matrix
    • ACTG Committees and Centers
    • Underrepresented Populations
    • Contact the LOC
  • Clinical Trials
    • About the Clinical Trials Process
    • Active Clinical Trials
    • Clinical Trials Resources
  • Sites
  • Community
    • Global Community Advisory Board
    • Community Resources
    • They Became My Family
  • Publications
  • News
    • COVID-19
    • In Memorium
    • Press Releases
    • Media Coverage
    • Network Spotlights
    • Newsletters
  • For Researchers
    • Submit a Proposal
    • Specimen Repository Website
    • HIV Databases

Whitman Walker Health CRS

Location

1701 14th Street, N.W.
Washington D.C., 20009
United States of America

https://www.whitman-walker.org/research-program

Phone202-939-7661
CRS Coordinator

Anna Wimpelberg
awimpelberg@whitman-walker.org
202-797-3589

CRS Leader

Sarah Henn
shenn@whitman-walker.org
202-745-6172

Studies
  • A5128: US Genomic Sampling
  • A5321: Decay of HIV-1 Reservoirs in Participants on Long-Term Antiretroviral Therapy: The ACTG HIV Reservoirs Cohort (AHRC) Study
  • A5324: A Randomized, Double-Blinded, Placebo-Controlled Trial Comparing Antiretroviral Intensification with Maraviroc and Dolutegravir with No Intensification or Intensification with Dolutegravir Alone for the Treatment of Cognitive Impairment in HIV 
  • A5332: REPRIEVE Trial
  • A5345: HIV Rebound & Control Biomarkers
  • A5354: Early ART in Acute HIV
  • A5360: MINMON Study-Monitoring SOF/VEL in Treatment Naïve, Chronic HCV Participants
  • A5366: Selective Estrogen Receptor Modulators to Enhance the Efficacy of Viral Reactivation with Histone Deacetylase Inhibitors
  • A5380: Glecaprevir/pibrentasvir Fixed-dose Combination Treatment for Acute Hepatitis C Virus Infection (PURGE-C)
  • A5395: A Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons with COVID-19
  • A5379: B-Enhancement of HBV vaccination in persons living with HIV (BEe-HIVe): Evaluation of HEPLISAV-B

Mission

The mission of the ACTG Network
is to cure HIV and reduce the
burden of disease due to HIV
and its complications, including
tuberculosis and viral hepatitis.

Useful Links

Government Resources
Clinical Trials Resources
Grants and Contracts
New Members

© ACTG. All Rights Reserved. | admin login